REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Reviva Pharmaceuticals Holdings, Inc.
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) dilution facts from SEC filings
Snapshot as of Sep 30, 2026, built from 24 SEC filings.
- Warrants outstanding
- 15 warrant series recorded as outstanding
Check another stock for dilution
Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.